preloader

1735(E)

(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals

National Pharmaceutical Pricing Authority

 

New Delhi, the 26th July, 2011

 

ORDER

S.O. 1735(E) – In implementation of directions given in order dated 01.06.2011 in W.P (c) 456/2011 (M/s Eli Lilly and Company India Pvt. Ltd. Vs. Union of India & Anr.) by the Hon’ble High Court of Delhi and review order passed by the Department of Pharmaceuticals by letter no. 31015-PI.I dated 31.05.2011 in respect of price fixation order S.O. No. 1775(E) dated 21.07.2010 fixing the prices of imported Insulin formulations, the matter has been reconsidered and re-examined in the National Pharmaceutical Pricing Authority (hereinafter mentioned as NPPA).

NPPA in its 121st Authority Meeting held on 22.07.2011 duly considered the aforesaid price fixation order and approved the prices of imported formulations considering the CIF prices claimed in Form IV of Drugs (Prices Control) Order, 1995 (hereinafter mentioned as DPCO 1995).  The Authority also considered and approved the guidelines in respect of MAPE / Margin for imported formulations having domestic / indigenous substitute.  Accordingly, prices for concerned imported formulations were approved with the margin as applicable to ensure fair and reasonable price to consumer public.

Therefore, in respect of above mentioned price fixation and in exercise of the powers, conferred by sub-paragraph (1)/(2)/(4)/(7) of paragraph 8 of the DPCO 1995 read with S.O. No. 637 (E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers, (NPPA) No. S.O. 1775(E), dated 21st July, 2010, in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the NPPA, hereby fixes/revises the prices as specified in column (4) of the table hereto annexed as the retail price/revised retail price, exclusive of excise duty, Sales Taxes/VAT and local taxes, if any, and in column (5) as equivalent MRP inclusive of excise duty, education cess, Sales Tax/VAT in relation to each of the formulation specified in the corresponding entry in column (2) of the said table with the pack size specified in the corresponding entries in column (3) thereof; manufactured/imported by M/s. Eli Lilly and Company (I) Pvt. Ltd.

TABLE

Sl. No. Name of the  formulation  Pack Size Retail Price  without   Excise Duty  Sales Tax /VAT  and Local Tax, if any  (Rs.) Equivalent MRP* inclusive of all  taxes   (Rs.)
(1) (2) (3) (4) (5)
1.

Monocomponent Insulin   Humalog Kwik Mix 25 Pen  100 IU/ml Each ml of 25% Insulin Lispro and 75%

Insulin Lispro Protamine Suspension contains:

100 IU Insulin Lispro PH. Eur (r-DNA origin)

Batch no. A706528H / Qty. 1500 Prefilled Pens

 3 ml Prefilled  Kwik Pen 482.33     501.62
2.

Monocomponent Insulin  Humalog Kwik Mix 50 Pen 100 IU/mlEach ml of 50% Insulin Lispro and 50%

Insulin Lispro Protamine Suspension contains:

100 IU Insulin Lispro PH. Eur (r-DNA origin)

Batch no. A713053G / Qty. 1500 Prefilled Pens

3 ml Prefilled  Kwik Pen   482.33 501.62
3.

 Monocomponent Insulin Humalog Kwik Pen 100 IU/ml (Insulin Lispro)

Each ml of Insulin Lispro contians:

100 IU Insulin Lispro Ph. Eur (r-DNA origin)

Batch no. A693971L/ Qty. 1500 Prefilled Pens

 3ml Prefilled Kwik Pen  482.33    501.62
4.

 Monocomponent Insulin  Humalog Mix 25 100 IU/ml  (Insulin Lispro)

Each ml contain

25% Insulin Lispro and 75% Insulin

Lispro Protamine suspension,

100 IU Insulin Lispro (r-DNA Origin)

Batch No. A716467C / Qty. 1500 Cartridge

  3ml        Cartridge  357.75  372.06
5.

Monocomponent Insulin  Humalog Mix 50 100IU/ml (Insulin Lispro)

Each ml contain

50% Insulin Lispro and

50% Insulin Lispro Protamine Suspension,

100 IU Insulin Lispro Ph. Eur. (r-DNA Origin)

Batch No. A708188A/ Qty. 30800 Cartridge

3ml     Cartridge  357.75   372.06
6.

Monocomponent Insulin  Humalog 100 IU/ml  (Insulin Lispro)

Each ml contain

100 IU Insulin Lispro Ph. Eur. (r-DNA origin)

Batch No. A715892A / Qty. 67925 Cartridge

3ml Cartridge   357.75  372.06

*Subject to actual payment of Government levies/taxes, as applicable.

Note :

  1. The prices fixed are the maximum retail prices in column no. (5) (Inclusive of excise duty, sales tax/VAT and local taxes if any) for the specified pack and packs of similar strength, and companies cannot claim exemption on any ground there from, unless specifically permitted by the Government/NPPA through an order.
  2. The companies / manufacturers may add taxes only if they have paid actually to the Government on the price mentioned in the column (4).  If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in the Form-V of DPCO, 1995.
  3. For different packing material used or, different drug delivery systems or any other special features/forms claimed, the retail prices, as specified in Column No. 4 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
  4. The manufacturer and marketing company for the above said formulation shall be required to take the requisite prior approval from the competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
  5. These prices/revised prices shall be made effective within 15 days of receipt of this order as required under sub para 14(1) of DPCO, 1995. The necessary price-list should also be issued as required under sub-paragraph (3) of paragraph 14 of the Drugs (Prices Control) Order, 1995.
  6. These prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented by the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
  7. The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the Essential Commodities Act, 1955.

PN/121/2011/F

F. No. 8(30)/2011/D.P./NPPA-Div.-II

(S. K. BHATT)
Deputy Director

Last Page Updated: 05-02-2019